HIV treatment simplification to elvitegravir/cobicistat/emtricitabine/tenofovir disproxil fumarate (E/C/F/TDF) plus darunavir: a pharmacokinetic study

Table 1 Baseline characteristics of study participants (n = 10)

Subject no.	Gender	Age, years	Weight, kg	eGFR, mL/min	Viral load, copies/mL	CD4, cells/mm³	Antiretroviral regimen (with tenofovir DF and emtricitabine)
1	Male	59	92.5	78	< 40	180	RAL 400 mg twice daily DRV 800 mg daily Ritonavir 100 mg daily
2	Male	47	89.5	60	< 40	510	RAL 400 mg twice daily DRV 800 mg daily Ritonavir 100 mg daily
3	Male	71	63	62	< 40	400	RAL 400 mg twice daily ATV 300 mg daily Ritonavir 100 mg daily
4	Male	55	101.5	85	< 40	900	RAL 400 mg twice daily DRV 800 mg daily Ritonavir 100 mg daily
5	Female	42	56	84	< 40	900	RAL 400 mg twice daily DRV 600 mg twice daily Ritonavir 100 mg twice daily
6	Male	33	85.5	102	< 40	410	RAL 400 mg twice daily ATV 300 mg daily Ritonavir 100 mg daily
7	Male	53	72	95	< 40	500	RAL 400 mg twice daily DRV 800 mg daily Ritonavir 100 mg daily
8	Male	56	95.5	74	< 40	700	DTG 50 mg daily DRV 800 mg daily Ritonavir 100 mg daily
9	Female	48	84	100	< 40	50	RAL 400 mg twice daily DRV 800 mg daily Ritonavir 100 mg daily
10	Male	47	98.5	75	134	1020	RAL 400 mg twice daily ATV 300 mg daily Ritonavir 100 mg daily

eGFR estimated glomerular filtration rate, RAL raltegravir, DTG dolutegravir, DRV darunavir, ATV atazanavir

ISSN: 1742-6405